On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the "Company" or "NurExone"), a pioneering biopharmaceutical company,

GlobeNewswireJun 22 04:04

NurExone Announces Expansion of ExoPTEN Patent Coverage With Notice of Allowance for Japanese Patent Application

TORONTO and HAIFA, Israel, June 11, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the "Company" or "NurExone"), a pioneering biopharmaceutical company

GlobeNewswireJun 11 20:44

NurExone Announces Voting Results From 2024 Annual Meeting of Shareholders

TORONTO and HAIFA, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the "Company" or "NurExone"), a pioneering biopharmaceutical company

GlobeNewswireJun 5 04:40

NurExone Biologic Inc.: Momentum and Market Growth

TipRanksMay 29 21:09

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, Moving Forward With FDA Guidelines for the Human Trials

TORONTO and HAIFA, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (the "Company" or "NurExone"), a pioneering biopharmaceutical company dev

GlobeNewswireMay 29 20:35

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

TORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the "Company" or "NurExone"), a pioneering biopharmaceutical company,

GlobeNewswireMay 18 04:04